Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib in Patients with Non-small Cell Lung Cancer
Background and objective Genetic variations of the epidermal growth factor receptor (EGFR) may alter the protein function and therapeutic efficacy of EGFR inhibitors. The aim of this study is to investigate the association between single nucleotide polymorphism rs2293347 in EGFR and the clinical out...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2011-08-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2011.08.02 |
| _version_ | 1818619723879809024 |
|---|---|
| author | Fei MA Binghe XU Dongxin LIN Tong SUN Yuankai SHI |
| author_facet | Fei MA Binghe XU Dongxin LIN Tong SUN Yuankai SHI |
| author_sort | Fei MA |
| collection | DOAJ |
| description | Background and objective Genetic variations of the epidermal growth factor receptor (EGFR) may alter the protein function and therapeutic efficacy of EGFR inhibitors. The aim of this study is to investigate the association between single nucleotide polymorphism rs2293347 in EGFR and the clinical outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib. Methods A total of 88 advanced NSCLC patients treated with gefitinib were analyzed in the present study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was conducted to analyze the genotype. The association study was performed between genotypes and clinical efficacy among 88 patients. Results rs2293347 was associated with the efficacy of gefitinib. The response rate for the rs2293347 GG was significantly higher than that for the GA or AA (71.4% vs 36.0%, P=0.002). rs2293347 GG genotype was also associated with longer progression-free survival compared with GA or AA genotype (10 months vs 3 months, P=0.005). No significant difference was shown on the overall survival (OS) (P=0.409). Conclusion rs2293347 polymorphism in exon 25 is associated with the clinical efficacy of gefitinib and may be a potential biomarker to predict the clinical outcome in advanced NSCLC patients treated with gefitinib. |
| first_indexed | 2024-12-16T17:42:01Z |
| format | Article |
| id | doaj.art-7ef83090baeb456c8b34ddd7b33c021e |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-16T17:42:01Z |
| publishDate | 2011-08-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-7ef83090baeb456c8b34ddd7b33c021e2022-12-21T22:22:33ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872011-08-0114864264510.3779/j.issn.1009-3419.2011.08.02Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung CancerFei MABinghe XUDongxin LINTong SUNYuankai SHIBackground and objective Genetic variations of the epidermal growth factor receptor (EGFR) may alter the protein function and therapeutic efficacy of EGFR inhibitors. The aim of this study is to investigate the association between single nucleotide polymorphism rs2293347 in EGFR and the clinical outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib. Methods A total of 88 advanced NSCLC patients treated with gefitinib were analyzed in the present study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was conducted to analyze the genotype. The association study was performed between genotypes and clinical efficacy among 88 patients. Results rs2293347 was associated with the efficacy of gefitinib. The response rate for the rs2293347 GG was significantly higher than that for the GA or AA (71.4% vs 36.0%, P=0.002). rs2293347 GG genotype was also associated with longer progression-free survival compared with GA or AA genotype (10 months vs 3 months, P=0.005). No significant difference was shown on the overall survival (OS) (P=0.409). Conclusion rs2293347 polymorphism in exon 25 is associated with the clinical efficacy of gefitinib and may be a potential biomarker to predict the clinical outcome in advanced NSCLC patients treated with gefitinib.http://dx.doi.org/10.3779/j.issn.1009-3419.2011.08.02Lung neoplasmsEpidermal growth factor receptor (EGFR)GefitinibSingle nucleotide polymorphism |
| spellingShingle | Fei MA Binghe XU Dongxin LIN Tong SUN Yuankai SHI Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib in Patients with Non-small Cell Lung Cancer Chinese Journal of Lung Cancer Lung neoplasms Epidermal growth factor receptor (EGFR) Gefitinib Single nucleotide polymorphism |
| title | Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer |
| title_full | Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer |
| title_fullStr | Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer |
| title_full_unstemmed | Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer |
| title_short | Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer |
| title_sort | effect of rs2293347 polymorphism in egfr on the clinical efficacy of gefitinib
in patients with non small cell lung cancer |
| topic | Lung neoplasms Epidermal growth factor receptor (EGFR) Gefitinib Single nucleotide polymorphism |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2011.08.02 |
| work_keys_str_mv | AT feima effectofrs2293347polymorphisminegfrontheclinicalefficacyofgefitinibinpatientswithnonsmallcelllungcancer AT binghexu effectofrs2293347polymorphisminegfrontheclinicalefficacyofgefitinibinpatientswithnonsmallcelllungcancer AT dongxinlin effectofrs2293347polymorphisminegfrontheclinicalefficacyofgefitinibinpatientswithnonsmallcelllungcancer AT tongsun effectofrs2293347polymorphisminegfrontheclinicalefficacyofgefitinibinpatientswithnonsmallcelllungcancer AT yuankaishi effectofrs2293347polymorphisminegfrontheclinicalefficacyofgefitinibinpatientswithnonsmallcelllungcancer |